US FDA Wades Into Reimbursement Issues With Upcoming Stakeholder Meeting On Alzheimer’s Drug Coverage, Evidence Challenges
Executive Summary
Convened by the Duke-Margolis Health Policy Center, the meeting later this month will not be open to the public. But the center expects to continue to engage with stakeholders on the issues in the coming weeks and months.
You may also be interested in...
Medicare Coverage For Aduhelm Conditioned On Randomized Trial Would Be ‘Unusual’ – McClellan
Former CMS chief Mark McClellan discusses what kind of study requirements Medicare might impose if it decides to only cover the new Alzheimer’s drug if in the context of further evidence generation.
Biogen/Eisai Will Explore Volume-Based Discounts For Aduhelm In Medicare
Deal with Veterans Administration also expected; companies say they will work with payers to ‘address’ pricing if patient population and uptake for their Alzheimer's drug are greater than expected.
All Alzheimer’s Eyes On Medicare: CMS Will Take The Lead On Tailoring Access To Aduhelm
Biogen/Eisai’s newly-approved Alzheimer’s drug could be headed to CMS’ Medicare advisory committee, which is chaired by vocal drug pricing reform advocate Peter Bach.